Breaking News, Trials & Filings

GSK’s Cervarix Gains Approval in Japan

GlaxoSmithKline gained approval for Cervarix in Japan, becoming the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare (MHLW).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline gained approval for Cervarix in Japan, becoming the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). The vaccine, which is formulated with GSK’s AS04 adjuvant system, has been licensed for the prevention of pre-cancerous lesions (cervical intraepithelial neoplasia – CIN 2 and 3) and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by human papillomavirus (HPV) types 16 and 18, in girls and women aged...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters